{"id":528410,"date":"2025-09-04T00:00:00","date_gmt":"2025-09-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0009-2025-biopharma-acute-coronary-syndrome-unmet-need-unmet-need-acute-coronary-syndrome-secondary-prevention\/"},"modified":"2026-04-21T11:11:27","modified_gmt":"2026-04-21T11:11:27","slug":"unnecv0009-2025-biopharma-acute-coronary-syndrome-unmet-need-unmet-need-acute-coronary-syndrome-secondary-prevention","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0009-2025-biopharma-acute-coronary-syndrome-unmet-need-unmet-need-acute-coronary-syndrome-secondary-prevention\/","title":{"rendered":"Acute Coronary Syndrome &#8211; Unmet Need &#8211; Unmet Need &#8211; Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US\/EU)"},"content":{"rendered":"<p>This report covers the 12-month post-hospital management of secondary prevention in <abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients. Reducing cardiovascular (<abbr title=\"cardiovascular\">CV<\/abbr>) residual risk and achieving guideline-recommended <abbr title=\"low-density lipoprotein cholesterol\">LDL-C<\/abbr> targets remains a significant unmet need, despite current lipid-lowering therapies having shown improved <abbr title=\"cardiovascular\">CV<\/abbr> outcomes in post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients. Emerging therapies offer promising avenues to further reduce recurrent <abbr title=\"cardiovascular\">CV<\/abbr> events through different lipid- and lipoprotein-targeted approaches. This report analyzes how current lipid-lowering therapies when added to statin treatment differ based on key attributes and their influence on physicians&#8217; prescribing behavior. It also explores unmet needs in residual <abbr title=\"cardiovascular\">CV<\/abbr> risk by lipid- and lipoprotein-lowering therapies for secondary prevention in <abbr title=\"acute coronary syndrome\">ACS<\/abbr> and evaluates whether emerging therapies can address these gaps.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do cardiologists evaluate the performance of existing post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> lipid-lowering therapies when added to statins across key clinical and non-clinical factors such as efficacy, convenience of administration, and pricing?<\/li>\n<li>What are the most significant gaps in post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> residual <abbr title=\"cardiovascular\">CV<\/abbr> risk treatment landscape?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>What trade-offs across different clinical attributes (e.g. risk reduction in <abbr title=\"cardiovascular\">CV<\/abbr> death, mortality or non-fatal myocardial infarction) would cardiologists be willing to make for a new drug for post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr>?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European cardiologists<\/p>\n<p><strong>Key drugs covered: <\/strong>Zetia \/ Ezetrol, Repatha, Praluent, Nexletol, Vascepa<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-528410","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-cardiovascular","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/528410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/528410\/revisions"}],"predecessor-version":[{"id":528710,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/528410\/revisions\/528710"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=528410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}